Skip to main content

Electronic Cigarettes clinical trials at UC Health

9 in progress, 7 open to eligible people

Showing trials for
  • Arterial Inflammation and E-Cigarettes

    open to eligible people ages 21-45

    Arterial inflammation will be compared using PET scanning in 3 groups: 1) Non-smokers, 2) Tobacco cigarette smokers, 3) Electronic cigarette users.

    at UCLA

  • E-cigarettes and Blood Vessel Function

    open to eligible people ages 21-45

    Randomized controlled trial of electronic cigarettes with nicotine, without nicotine, and sham control, on endothelial function and markers of oxidative stress.

    at UCLA

  • E-Cigarettes and SNA

    open to eligible people ages 21-45

    Randomized controlled trial of electronic cigarettes with nicotine, without nicotine, and sham control, on sympathetic nerve activity and markers of oxidative stress.

    at UCLA

  • E-cigarettes, Nicotine Inhaler, and Blood Vessel Function

    open to eligible people ages 21-45

    Randomized controlled trial of electronic cigarettes with nicotine, without nicotine, nicotine inhaler, and sham-control on endothelial function, oxidative stress and sympathetic nerve activity

    at UCLA

  • ECigs, Inflammation and Oxidative Stress

    open to eligible people ages 21-45

    Randomized controlled trial of acute use of electronic cigarette effect on oxidative stress and inflammation.

    at UCLA

  • Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes

    open to eligible people ages 21-70

    This is an observational, crossover design that will examine the pharmacokinetics and pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic cigarette.

    at UCSF

  • Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power

    open to eligible people ages 21 years and up

    This study will examine the short-term cardiovascular (CV) effects of e-cigarette device power in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette power on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.

    at UCSF

  • Cigarette Harm Reduction With Electronic Cigarette Use

    Sorry, not yet accepting patients

    This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.

    at UCSF

  • Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH

    Sorry, not yet accepting patients

    This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim of the study is to assess the impact of changes in e-liquid pH on nicotine pharmacokinetics, cardiovascular, and subjective effects of e-cigarettes.

    at UCSF

Last updated: